Ethereum Needs ,700 Breakout to Turn Upgrade Optimism Into Price Action
| | | |

Ethereum Needs $1,700 Breakout to Turn Upgrade Optimism Into Price Action

Ethereum could be getting its first major hard fork since the Fusaka Upgrade in December 2025. Developers have shared the EIP-8182 proposal, dubbed the HegotĆ” hard fork. There have been a lot of talks about this upgrade as it looks to change how we handle transaction data on-chain. The community is filled with excitement over…

The Market Finally Broadened Out, And This Group Is Next
| | | |

The Market Finally Broadened Out, And This Group Is Next

A real rally does not ride on five stocks. It spreads. Yesterday, the market ripped higher, and this time it was not just the usual tech giants doing the heavy lifting. The small and mid-sized names led the way, with the Russell 2000 jumping over 3%, beating the big indexes. That matters more than the…

The Smartest Way to Own SpaceX
| | | |

The Smartest Way to Own SpaceX

The biggest IPO in history prices Friday, and the smart money is NOT lining up to buy it right away. Don’t get me wrong. SpaceX is the most important private company on the planet, and the space economy is on fire. But there’s a difference between believing in a business and overpaying to own it…

Ethereum Bulls Need ,680 Breakout to Turn Stability Into Recovery
| | | |

Ethereum Bulls Need $1,680 Breakout to Turn Stability Into Recovery

Beneath the recent market slump, Ethereum () has been showing signs of growing momentum. Although the ETH price has been falling in the last week, open interest in Ethereum terms has hit a new all-time high on Binance. Also, Ethereum is approaching 200 million non-empty wallets. This bullish sign suggests a rise in ETH investor…

Left For Dead a Year Ago. Now It Cannot Stop Making Money.
| | | |

Left For Dead a Year Ago. Now It Cannot Stop Making Money.

Most biotechs burn cash and beg for more. This one is printing it. Liquidia (LQDA) spent years as a classic biotech lottery ticket. One drug, one FDA decision, a lawsuit hanging over the whole thing. You either guessed right, or you got cut in half. That is the kind of name I usually watch from…

Did Traders Sell Bitcoin to Chase SpaceX?
| | | |

Did Traders Sell Bitcoin to Chase SpaceX?

, and several AI winners got smoked at the same time. Coincidence, or was the largest IPO in history draining liquidity from markets? Fed and dollar narratives struggle to explain Bitcoin’s latest rout Gold, Bitcoin and AI winners sold off at the same time SpaceX reportedly attracted $250 billion chasing $75 billion of stock Excess…

Bitcoin Sell-Off Exposes Fragility Across Smaller Layer-2 Networks
| | | |

Bitcoin Sell-Off Exposes Fragility Across Smaller Layer-2 Networks

The Bitcoin ecosystem continues to suffer one hit after another. In a shocking turn of events Botanix a major Bitcoin Layer-2 project, is closing its doors. Botanix has announced that users have until July 9 to withdraw their assets. This exit happens at a terrible time, arriving right in the middle of a brutal Bitcoin…

I’m not rushing into the SpaceX IPO
| | | |

I’m not rushing into the SpaceX IPO

A company that hasn’t traded a single share yet is about to be worth more than the entire American aerospace industry. Think about that for a minute. Not just more than Boeing (BA). More than Boeing, GE Aerospace, and every other aerospace and defense company in the S&P 500 put together. That is what SpaceX…

Could Bitcoin Break Below 60K Amid Middle East, Inflation and Liquidity Concerns
| | | |

Could Bitcoin Break Below 60K Amid Middle East, Inflation and Liquidity Concerns

BTC falls towards 60k US CPI is expected to rise to 4.2% YoY, a 3year high BTC ETF outflows & rising competition for capital BTC Technical Analysis is falling, slipping back below 63k after the U.S. launched a new wave of strikes on Iran, triggering a risk-off mood across financial markets ahead of key U.S….

The Biotech Everyone Gave Up On Is Quietly Rebuilding
| | | |

The Biotech Everyone Gave Up On Is Quietly Rebuilding

Biogen’s (BIIB) biggest drugs are dying. The stock is climbing anyway. For a company whose old engine, the big multiple sclerosis names, has been winding down for years, that does not add up on the surface. So what is the market starting to see that the headlines are not? Look at what Biogen has actually…

End of content

End of content